Live feed09:15:00·5mPRReleasevia QuantisnowAbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple MyelomaByQuantisnow·Wall Street's wire, on your screen.ABBV· AbbVie Inc.Health Care